Annual report
4574.TEDINET S100XSJ2
Period2025-01-01 → 2025-12-31
Filed2026-03-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 144
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.4bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥6.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2023-01-01 → 2023-12-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.0bn | 2022-01-01 → 2022-12-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.3bn | 2021-01-01 → 2021-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥459m | 2025-01-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | ¥629m | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | ¥482m | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥688m | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥3.4bn | 2022-01-01 → 2022-12-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥6.1bn | 2021-01-01 → 2021-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥958m | 2025-01-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥565m | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥923m | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥898m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥3.6bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥4.9bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥9.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥923m | 2025-01-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | ¥898m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥12.3bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥12.9bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥13.2bn | at 2023-12-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥15.0bn | at 2022-12-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥22.5bn | at 2021-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.8bn | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥4.9bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.5bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2023-12-31v | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-12-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥12.8bn | at 2021-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.3bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.2bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2022-12-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥5.5bn | at 2021-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥814m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥362m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥307m | 2023-01-01 → 2023-12-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.0bn | 2022-01-01 → 2022-12-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.6bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥142m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.2bn | 2023-01-01 → 2023-12-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥190m | 2022-01-01 → 2022-12-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.6bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2023-01-01 → 2023-12-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥997m | 2022-01-01 → 2022-12-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥4.0bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥18.38 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.9 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-76.25 | 2023-01-01 → 2023-12-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-112.26 | 2022-01-01 → 2022-12-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-220.52 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥169.51 | at 2025-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥158.67 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥134.93 | at 2023-12-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥184.6 | at 2022-12-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥293.88 | at 2021-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 69.4% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.0% | at 2023-12-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2022-12-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.8% | at 2021-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 11.2% | 2025-01-01 → 2025-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -48.9% | 2023-01-01 → 2023-12-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | -47.0% | 2022-01-01 → 2022-12-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | -53.9% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 220 | at 2025-12-31 | Cons. | Number of employees |
| Employees | 214 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 208 | at 2023-12-31v | Cons. | Number of employees |
| Employees | 210 | at 2022-12-31v | Cons. | Number of employees |
| Employees | 264 | at 2021-12-31d | Cons. | Number of employees |
| Revenue | ¥5.6bn | 2025-01-01 → 2025-12-31 | Standalone | Net sales |
| Revenue | ¥5.5bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥5.4bn | 2023-01-01 → 2023-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.6bn | 2022-01-01 → 2022-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥10.6bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥282m | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | ¥501m | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | ¥332m | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥947m | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥3.3bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥5.9bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥840m | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥829m | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | ¥781m | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥3.7bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥5.0bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥9.3bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥11.5bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥12.1bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥12.2bn | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.3bn | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.9bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.5bn | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥4.7bn | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥8.0bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥7.4bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥6.0bn | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥7.5bn | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥12.4bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥3.2bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.5bn | at 2024-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥15.56 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.34 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-78.63 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-113.64 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-213.03 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥3.3 | 2025-01-01 → 2025-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥158.72 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥147.67 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥120.52 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥171.91 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥284.83 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 69.6% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.1% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.1% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.4% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.6% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.2% | 2025-01-01 → 2025-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.4% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -55.1% | 2023-01-01 → 2023-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -49.8% | 2022-01-01 → 2022-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -53.6% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 50,636,900 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 50,636,900 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 50,436,900 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 44,136,900 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 44,136,900 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 193 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 186 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 178 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 175 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 226 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 58
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-01-01 → 2025-12-31 | ¥5m |
| Otherother segments | revenue external | 2025-01-01 → 2025-12-31 | ¥5m |
| Otherother segments | segment assets | at 2025-12-31 | ¥13m |
| Otherother segments | segment profit | 2025-01-01 → 2025-12-31 | −¥22m |
| Reconciling Itemsreconciling | capex | 2025-01-01 → 2025-12-31 | ¥63m |
| Reconciling Itemsreconciling | depreciation | 2025-01-01 → 2025-12-31 | ¥34m |
| Reconciling Itemsreconciling | segment assets | at 2025-12-31 | ¥5.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-12-31 | −¥837m |
| Infection Control Businessreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥23m |
| Infection Control Businessreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥12m |
| Infection Control Businessreportable segment | employees | at 2025-12-31 | 34 pure |
| Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥619m |
| Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥619m |
| Infection Control Businessreportable segment | segment assets | at 2025-12-31 | ¥748m |
| Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | −¥254m |
| Pharmaceuticals Businessreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥253m |
| Pharmaceuticals Businessreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥217m |
| Pharmaceuticals Businessreportable segment | employees | at 2025-12-31 | 159 pure |
| Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥5.8bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥5.8bn |
| Pharmaceuticals Businessreportable segment | segment assets | at 2025-12-31 | ¥6.3bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥1.6bn |
| —segment total | employees | at 2025-12-31 | 193 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-01-01 → 2025-12-31 | ¥276m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-01-01 → 2025-12-31 | ¥230m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-12-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-12-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-12-31 | ¥7.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-12-31 | ¥1.3bn |
| Otherother segments | revenue | 2024-01-01 → 2024-12-31 | ¥5m |
| Otherother segments | revenue external | 2024-01-01 → 2024-12-31 | ¥5m |
| Otherother segments | segment assets | at 2024-12-31 | ¥13m |
| Otherother segments | segment profit | 2024-01-01 → 2024-12-31 | −¥12m |
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥67m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥24m |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥5.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥837m |
| Infection Control Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥4m |
| Infection Control Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥12m |
| Infection Control Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥508m |
| Infection Control Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥508m |
| Infection Control Businessreportable segment | segment assets | at 2024-12-31 | ¥710m |
| Infection Control Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥467m |
| Pharmaceuticals Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥137m |
| Pharmaceuticals Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥220m |
| Pharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥5.8bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥5.8bn |
| Pharmaceuticals Businessreportable segment | segment assets | at 2024-12-31 | ¥6.3bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-01-01 → 2024-12-31 | ¥142m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-01-01 → 2024-12-31 | ¥232m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-12-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-12-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-12-31 | ¥7.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-12-31 | ¥1.5bn |
| Infection Control Businessreportable segment | employees | at 2025-12-31 | 33 pure |
| Pharmaceuticals Businessreportable segment | employees | at 2025-12-31 | 133 pure |
| —segment total | employees | at 2025-12-31 | 166 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,538
| Item | Context | Value | Unit |
|---|---|---|---|
| Commission fee sga | Prior1YearDuration_NonConsolidatedMember | 309000000 | JPY |
| Commission fee sga | CurrentYearDuration_NonConsolidatedMember | 324000000 | JPY |
| Research and development expenses sga | Prior1YearDuration_NonConsolidatedMember | 183000000 | JPY |
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 208000000 | JPY |
| Depreciation sga | Prior1YearDuration_NonConsolidatedMember | 13000000 | JPY |
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 23000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-03-24 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第80期（自 2025年１月１日 至 2025年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)大幸薬品株式会社 | |
| Company name in english cover page | FilingDateInstant | TAIKO PHARMACEUTICAL CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 柴田 高 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪府吹田市内本町三丁目34番14号（同所は登記上の本店所在地で実際の業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪府大阪市西区西本町一丁目４番１号 オリックス本町ビル16階 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)０６－４３９１－１１１０（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)コーポレート本部 経理部長 中條 亨 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E22560 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45740 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)大幸薬品株式会社 | |
| Filer name in english | FilingDateInstant | TAIKO PHARMACEUTICAL CO.,LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2025-01-01 | |
| Current period end date | FilingDateInstant | 2025-12-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2025-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Comparative period end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |